|
Description
| Alnylam Pharmaceuticals, Inc. (Cambridge, MA) and Cenix BioScience GmbH (Dresden, Germany), the premier provider of advanced RNAi research services, have entered into a research alliance and licensing agreement. Under the terms of the agreement executed through Ribopharma AG, the German affiliate of Alnylam, Cenix was granted a non-exclusive license to market research services under a fundamental patent in RNA interference (RNAi), and will pay annual fees and royalties on sales of licensed services. Alnylam will also benefit from Cenix's leading expertise in the design and testing of small interfering RNAs (siRNAs). The patent licensed to Cenix... |
More articles from BIOTECH Patent News
Isotechnika obtains United States patent.(Brief Article), February 01, 2004
ZymoGenetics obtains United States patent.(Brief Article), February 01, 2004
North Carolina State University obtains United States patent.(Brief Ar..., February 01, 2004
Tokai University obtains United States patent.(Brief Article), February 01, 2004
Boston Medical Center obtains United States patent.(Boston Medical Cen..., February 01, 2004
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
(cenix%20bioscience%20gmbh)%20%20&position=1)